Prostaglandin E2 Receptor EP4 Subtype Market Size, Share, Growth, and Industry Analysis, By Type (KAG-308, CR 6086, ONO 4232, ONO 4578, E 7046, EP4-R Antagonist, AAT 008), By Application (Cancer, Autoimmune Disease, Others), and Regional Forecast to 2031

Updated On: 22 April 2024

Prostaglandin E2 Receptor EP4 Subtype MarketReport Overview

• 

• Request a Free Sample to learn more about this report

The global prostaglandin E2 receptor EP4 subtype market size was valued at USD 137.75 million in 2021. As per our research, the market is expected to reach USD 352.34 million by 2027, exhibiting a CAGR of 16.94% during the forecast period. The COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels.

Prostaglandin E2 receptors, particularly the EP4 subtype, play a pivotal role in various physiological processes and have garnered significant attention in the healthcare sector. EP4 receptors are involved in mediating the effects of prostaglandin E2, a lipid molecule that acts as a signaling molecule in the body. These receptors are found on the surface of various cell types and are known to modulate inflammatory responses, immune function, and cell proliferation. Additionally, EP4 receptors have been linked to cancer growth and progression, making them a target for potential cancer therapies.

The prostaglandin E2 receptor EP4 subtype market growth attributed to several driving factors. One of the primary drivers is the increased prevalence of chronic inflammatory diseases such as asthma, arthritis, and inflammatory bowel disease. EP4 receptors are involved in the pathogenesis of these diseases, and the rising incidence of such conditions has fueled the demand for EP4-targeted therapies. Another unique driver for the EP4 market is the growing recognition of the role of EP4 in cancer. EP4 receptors have been implicated in the growth and progression of various types of cancer. Researchers are investigating EP4 antagonists as potential cancer therapies, either as standalone treatments or in combination with other therapeutic modalities. This focus on targeting the EP4 receptor for cancer treatment sets it apart from many other drug classes.

COVID-19 Impact: Demand Surged Due to Elevated PGE2 Levels in COVID-19 Patients

The COVID-19 pandemic had a profound impact on the market, particularly in the context of heightened demand and emerging research into its therapeutic potential. As the world grappled with the challenges posed by the SARS-CoV-2 virus, the role of EP4 receptors in mediating the effects of prostaglandin E2 (PGE2) became increasingly significant.

During the pandemic, one of the striking observations was the surge in demand for therapies that could address the inflammation and lung-related complications associated with COVID-19. PGE2, a pivotal mediator of inflammation in the lungs, was found to be elevated in patients affected by the virus. The EP4 subtype of the PGE2 receptor, known for its involvement in various physiological and pathological processes, has gained attention as a potential therapeutic target.

Studies conducted during the pandemic demonstrated that blocking the EP4 subtype of the PGE2 receptor could effectively reduce inflammation and improve lung function in animal models of COVID-19. These findings ignited substantial interest in the development of EP4 antagonists as a potential treatment for the respiratory distress and inflammation commonly seen in COVID-19 patients. Clinical trials were initiated to rigorously assess the safety and efficacy of these EP4 antagonists in actual patient populations. Beyond the scope of treating COVID-19-related lung inflammation, the pandemic spurred research into the broader applications of EP4 agonists. These investigations explored their potential to address additional conditions associated with COVID-19, such as acute kidney injury and neuroinflammation. The unprecedented challenges posed by the pandemic accelerated the exploration of EP4-related therapies, highlighting the adaptability and responsiveness of the healthcare and pharmaceutical industries in times of crisis.

Latest Trends

"Advances in Neuroscientific Understanding to Reveal EP4 Antagonists' Potential"

In recent years, there has been a surge of interest in the potential use of the EP4 subtype for treating central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This growing interest is primarily driven by compelling preclinical evidence suggesting that EP4 antagonists hold promise for improving cognitive function, mitigating inflammation, and providing protection against neurodegeneration in these debilitating conditions.

The foundation of this enthusiasm lies in preclinical studies that have demonstrated the cognitive-enhancing effects of EP4 antagonists in animal models of Alzheimer's and Parkinson's diseases, as well as their ability to alleviate inflammation and safeguard against neurodegeneration in animal models of multiple sclerosis. These promising findings have spurred the exploration of EP4 antagonists as potential game-changers in the realm of CNS disorder treatments.

To bring this potential to fruition, numerous clinical trials are currently in progress to assess the safety and efficacy of EP4 antagonists in patients grappling with CNS disorders, including mild to moderate Alzheimer's disease, Parkinson's disease, and multiple sclerosis. By meticulously evaluating the outcomes of these trials, researchers aim to determine whether EP4 antagonists can indeed be harnessed as effective tools in combating CNS disorders, potentially offering newfound hope to patients and their families.

Segmentation

• 

• Request a Free Sample to learn more about this report

•  By Type Analysis

According to type, the market can be segmented into various categories, including KAG-308, CR 6086, ONO 4232, ONO 4578, E 7046, EP4-R antagonist, and AAT 008.

• By Application Analysis

Based on application, the market can be divided into categories such as cancer, autoimmune disease, and others.

Driving Factors

"Increased Prevalence of Chronic Inflammatory Diseases to Amplify Market Growth"

The prostaglandin E2 receptor EP4 subtype market is being driven by the rising prevalence of chronic inflammatory diseases such as asthma, arthritis, and inflammatory bowel disease. EP4 receptors are involved in the pathogenesis of these diseases, leading to increased demand for EP4-targeted therapies. As the global population continues to age and lifestyle factors contribute to the surge in these conditions, the need for effective treatment options further amplifies, making EP4 antagonists a compelling avenue for medical intervention. Additionally, the growing awareness among healthcare professionals and patients about the potential benefits of EP4-targeted therapies is contributing to this increased demand.

"Growing Recognition of EP4 in Cancer to Potentially Improve Patient Treatment"

The role of EP4 receptors in cancer growth and progression has gained recognition, driving research and development efforts to develop EP4 antagonists as potential cancer therapies. This unique driver sets the EP4 market apart from other drug classes. As a result, pharmaceutical companies are increasingly investing in innovative approaches to harness the therapeutic potential of EP4 antagonists, aiming to provide new avenues for cancer treatment and potentially improve patient outcomes in the fight against cancer.

Restraining Factor

"EP4 Antagonist Side Effects can Leads to Kidney Damage and Cardiovascular Problems"

The side effects of EP4 antagonists, including nausea, vomiting, diarrhea, headache, dizziness, fatigue, abdominal pain, and rash, are typically mild and transient but may be more severe in rare cases, potentially leading to liver or kidney damage, gastrointestinal bleeding, or cardiovascular problems. Moreover, the long-term safety of these drugs, particularly for extended use, requires extensive research due to the current lack of comprehensive data in this regard.

Regional Insights

• 

• Request a Free Sample to learn more about this report

"North America to Lead Due to Region’s High Prevalence of Chronic Inflammatory Diseases and Cancer"

North American region holds the largest prostaglandin E2 receptor EP4 subtype market share. The region boasts a robust healthcare infrastructure and a high prevalence of chronic inflammatory diseases and cancer, driving demand for EP4-targeted treatments.

Key Industry Players

"Key Players Focus on Partnerships to Gain a Competitive Advantage"

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Market Players Profiled

• AskAt (Japan)
• Eisai Inc (U.S.)
• Kaken Pharmaceutical (Japan)
• Ono Pharmaceutical (Japan)
• Rottapharm Biotech (Italy)
• Eli Lilly (U.S.)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.